CompetitionKey questions remain about RLAY's ability to adapt to a shifting treatment landscape and combination partners in 2L mBC.
Development RisksRisks include negative clinical data, slower-than-expected development timelines, and setbacks in later-stage trials.
Financial PerformanceThe licensing agreement for lirafugratinib appears heavily back-end loaded, leading to a lowered price target for Relay Therapeutics.